48,830
edits
Line 124: | Line 124: | ||
==Molecular== | ==Molecular== | ||
*+/-[[BRCA2 mutation]].<ref name=pmid28067867>{{cite journal |authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG |title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories |journal=Nat Commun |volume=8 |issue= |pages=13671 |date=January 2017 |pmid=28067867 |pmc=5227331 |doi=10.1038/ncomms13671 |url=}}</ref> | *+/-[[BRCA2 mutation]].<ref name=pmid28067867>{{cite journal |authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG |title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories |journal=Nat Commun |volume=8 |issue= |pages=13671 |date=January 2017 |pmid=28067867 |pmc=5227331 |doi=10.1038/ncomms13671 |url=}}</ref> | ||
Note: | |||
*BRCA1 associated prostate cancer seems to be less common/less studied.<ref name=pmid29433453>{{cite journal |vauthors=Ibrahim M, Yadav S, Ogunleye F, Zakalik D |title=Male BRCA mutation carriers: clinical characteristics and cancer spectrum |journal=BMC Cancer |volume=18 |issue=1 |pages=179 |date=February 2018 |pmid=29433453 |pmc=5809938 |doi=10.1186/s12885-018-4098-y |url=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4098-y }}</ref> | |||
==See also== | ==See also== |
edits